In a bid to bolster its neuroscience pipeline, Lilly has entered into a collaboration agreement with QurAlis to discover, develop and commercialise QRL-204, a splice -switching antisense oligonucleotide for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The deal, which is worth up to US$622 M, will leverage QurAlis’ FlexASOTM splice modulator platform to discover new UNC13A-targeted therapies for ALS. The deal comes shortly after Amylyx withdrew its ALS drug Relyvrio from the US and Canadian markets after a confirmatory trial failure.